Q4 2023: Eventful quarter caps transformative year

Important events during the fourth quarter

• Net sales increased by 8% (9% adjusted for currency effects) to SEK 156 m (144).
• The EBITDA margin amounted to 12% (11) or 15% adjusted for items affecting
  comparability.
• Probi launched Probi® Sensia, a brand new product concept in mental health.
• Probi launched two new scientifically proven synbiotic solutions together with Clasado Biosciences at Supply Side West in Las Vegas.
• Per Lindblad took over as CFO on November 1st
• The Board of Directors proposed a dividend for the fiscal year 2023 of a total of SEK 14,8m, corresponding to SEK 1,30 per share.

Read the entire report here.